StreetInsider.com News Articles

HEALEY ALS Platform Trial Regimen I expands to 240 participants

Wed, 27 May 2026 10:41:00 -0400

Highlights:

Neurizon announces an expansion to the size of Regimen I intended to support a larger and more informative dataset, with accelerated time to topline readout and no change in funding requirements
Increase in sample size driven by enrolment rate exceeding original expectations and the absence of a concurrent regimen during the expected recruitment period
Regimen I expands from 160 to 240 participants to maintain statistical power for the primary endpoint aligned with the original trial assumptions
The increased sample size allows more robust analysis of subgroups and biomarkers and ensures a fully powered study at topline results
Based on current

HEALEY ALS Platform Trial Regimen I expands to 240 participants

Wed, 27 May 2026 10:41:00 -0400

Highlights:
Neurizon announces an expansion to the size of Regimen I intended to support a larger and more informative dataset, with accelerated time to topline readout and no change in funding requirements
Increase in sample size driven by enrolment rate exceeding original expectations and the absence of a concurrent regimen during the expected recruitment period
Regimen I expands from 160 to 240 participants to maintain statistical power for the primary endpoint aligned with the original trial assumptions
The increased sample size allows more robust analysis of subgroups and biomarkers and ensures a fully powered study at topline results
Based on current

HEALEY ALS Platform Trial Regimen I expands to 240 participants

Wed, 27 May 2026 10:41:00 -0400

Highlights:
Neurizon announces an expansion to the size of Regimen I intended to support a larger and more informative dataset, with accelerated time to topline readout and no change in funding requirements
Increase in sample size driven by enrolment rate exceeding original expectations and the absence of a concurrent regimen during the expected recruitment period
Regimen I expands from 160 to 240 participants to maintain statistical power for the primary endpoint aligned with the original trial assumptions
The increased sample size allows more robust analysis of subgroups and biomarkers and ensures a fully powered study at topline results
Based on current

HEALEY ALS Platform Trial Regimen I expands to 240 participants

Wed, 27 May 2026 10:41:00 -0400

Highlights:
Neurizon announces an expansion to the size of Regimen I intended to support a larger and more informative dataset, with accelerated time to topline readout and no change in funding requirements
Increase in sample size driven by enrolment rate exceeding original expectations and the absence of a concurrent regimen during the expected recruitment period
Regimen I expands from 160 to 240 participants to maintain statistical power for the primary endpoint aligned with the original trial assumptions
The increased sample size allows more robust analysis of subgroups and biomarkers and ensures a fully powered study at topline results
Based on current

HEALEY ALS Platform Trial Regimen I expands to 240 participants

Wed, 27 May 2026 10:41:00 -0400

Highlights:
Neurizon announces an expansion to the size of Regimen I intended to support a larger and more informative dataset, with accelerated time to topline readout and no change in funding requirements
Increase in sample size driven by enrolment rate exceeding original expectations and the absence of a concurrent regimen during the expected recruitment period
Regimen I expands from 160 to 240 participants to maintain statistical power for the primary endpoint aligned with the original trial assumptions
The increased sample size allows more robust analysis of subgroups and biomarkers and ensures a fully powered study at topline results
Based on current

HEALEY ALS Platform Trial Regimen I expands to 240 participants

Wed, 27 May 2026 10:41:00 -0400

Highlights:
Neurizon announces an expansion to the size of Regimen I intended to support a larger and more informative dataset, with accelerated time to topline readout and no change in funding requirements
Increase in sample size driven by enrolment rate exceeding original expectations and the absence of a concurrent regimen during the expected recruitment period
Regimen I expands from 160 to 240 participants to maintain statistical power for the primary endpoint aligned with the original trial assumptions
The increased sample size allows more robust analysis of subgroups and biomarkers and ensures a fully powered study at topline results
Based on current

HEALEY ALS Platform Trial Regimen I expands to 240 participants

Wed, 27 May 2026 10:41:00 -0400

Highlights:
Neurizon announces an expansion to the size of Regimen I intended to support a larger and more informative dataset, with accelerated time to topline readout and no change in funding requirements
Increase in sample size driven by enrolment rate exceeding original expectations and the absence of a concurrent regimen during the expected recruitment period
Regimen I expands from 160 to 240 participants to maintain statistical power for the primary endpoint aligned with the original trial assumptions
The increased sample size allows more robust analysis of subgroups and biomarkers and ensures a fully powered study at topline results
Based on current

HEALEY ALS Platform Trial Regimen I expands to 240 participants

Wed, 27 May 2026 10:41:00 -0400

Highlights:
Neurizon announces an expansion to the size of Regimen I intended to support a larger and more informative dataset, with accelerated time to topline readout and no change in funding requirements
Increase in sample size driven by enrolment rate exceeding original expectations and the absence of a concurrent regimen during the expected recruitment period
Regimen I expands from 160 to 240 participants to maintain statistical power for the primary endpoint aligned with the original trial assumptions
The increased sample size allows more robust analysis of subgroups and biomarkers and ensures a fully powered study at topline results
Based on current

HEALEY ALS Platform Trial Regimen I expands to 240 participants

Wed, 27 May 2026 10:41:00 -0400

Highlights:
Neurizon announces an expansion to the size of Regimen I intended to support a larger and more informative dataset, with accelerated time to topline readout and no change in funding requirements
Increase in sample size driven by enrolment rate exceeding original expectations and the absence of a concurrent regimen during the expected recruitment period
Regimen I expands from 160 to 240 participants to maintain statistical power for the primary endpoint aligned with the original trial assumptions
The increased sample size allows more robust analysis of subgroups and biomarkers and ensures a fully powered study at topline results
Based on current

HEALEY ALS Platform Trial Regimen I expands to 240 participants

Wed, 27 May 2026 10:41:00 -0400

Highlights:
Neurizon announces an expansion to the size of Regimen I intended to support a larger and more informative dataset, with accelerated time to topline readout and no change in funding requirements
Increase in sample size driven by enrolment rate exceeding original expectations and the absence of a concurrent regimen during the expected recruitment period
Regimen I expands from 160 to 240 participants to maintain statistical power for the primary endpoint aligned with the original trial assumptions
The increased sample size allows more robust analysis of subgroups and biomarkers and ensures a fully powered study at topline results
Based on current

HEALEY ALS Platform Trial Regimen I expands to 240 participants

Wed, 27 May 2026 10:41:00 -0400

Highlights:
Neurizon announces an expansion to the size of Regimen I intended to support a larger and more informative dataset, with accelerated time to topline readout and no change in funding requirements
Increase in sample size driven by enrolment rate exceeding original expectations and the absence of a concurrent regimen during the expected recruitment period
Regimen I expands from 160 to 240 participants to maintain statistical power for the primary endpoint aligned with the original trial assumptions
The increased sample size allows more robust analysis of subgroups and biomarkers and ensures a fully powered study at topline results
Based on current

HEALEY ALS Platform Trial Regimen I expands to 240 participants

Wed, 27 May 2026 10:41:00 -0400

Highlights:
Neurizon announces an expansion to the size of Regimen I intended to support a larger and more informative dataset, with accelerated time to topline readout and no change in funding requirements
Increase in sample size driven by enrolment rate exceeding original expectations and the absence of a concurrent regimen during the expected recruitment period
Regimen I expands from 160 to 240 participants to maintain statistical power for the primary endpoint aligned with the original trial assumptions
The increased sample size allows more robust analysis of subgroups and biomarkers and ensures a fully powered study at topline results
Based on current

HEALEY ALS Platform Trial Regimen I expands to 240 participants

Wed, 27 May 2026 10:41:00 -0400

Highlights:
Neurizon announces an expansion to the size of Regimen I intended to support a larger and more informative dataset, with accelerated time to topline readout and no change in funding requirements
Increase in sample size driven by enrolment rate exceeding original expectations and the absence of a concurrent regimen during the expected recruitment period
Regimen I expands from 160 to 240 participants to maintain statistical power for the primary endpoint aligned with the original trial assumptions
The increased sample size allows more robust analysis of subgroups and biomarkers and ensures a fully powered study at topline results
Based on current

HEALEY ALS Platform Trial Regimen I expands to 240 participants

Wed, 27 May 2026 10:41:00 -0400

Highlights:
Neurizon announces an expansion to the size of Regimen I intended to support a larger and more informative dataset, with accelerated time to topline readout and no change in funding requirements
Increase in sample size driven by enrolment rate exceeding original expectations and the absence of a concurrent regimen during the expected recruitment period
Regimen I expands from 160 to 240 participants to maintain statistical power for the primary endpoint aligned with the original trial assumptions
The increased sample size allows more robust analysis of subgroups and biomarkers and ensures a fully powered study at topline results
Based on current

Elanco executive joins Neurizon board as observer

Wed, 26 Nov 2025 18:16:41 -0400

Neurizon Therapeutics Limited (ASX: NUZ; OTCQB: NUZTF) announced the appointment of Justine Conway as a board observer. Conway serves as Global Head of Business Development at Elanco Animal Health (NYSE: ELAN).

The appointment follows an exclusive global license agreement between the companies for Monepantel, the active pharmaceutical ingredient in Neurizon's NUZ-001 drug candidate, announced in July 2025. The agreement provides Neurizon access to animal safety data and manufacturing data needed for clinical trials and potential regulatory approvals.

Conway brings over 20 years of experience in healthcare and animal health industries. She joined Elanco in 2020 after working in investment banking at Macquarie

Elanco executive joins Neurizon board as observer

Wed, 26 Nov 2025 18:16:41 -0400

Neurizon Therapeutics Limited (ASX: NUZ; OTCQB: NUZTF) announced the appointment of Justine Conway as a board observer. Conway serves as Global Head of Business Development at Elanco Animal Health (NYSE: ELAN).

The appointment follows an exclusive global license agreement between the companies for Monepantel, the active pharmaceutical ingredient in Neurizon's NUZ-001 drug candidate, announced in July 2025. The agreement provides Neurizon access to animal safety data and manufacturing data needed for clinical trials and potential regulatory approvals.

Conway brings over 20 years of experience in healthcare and animal health industries. She joined Elanco in 2020 after working in investment banking at Macquarie

Elanco executive joins Neurizon board as observer

Wed, 26 Nov 2025 18:16:41 -0400

Neurizon Therapeutics Limited (ASX: NUZ; OTCQB: NUZTF) announced the appointment of Justine Conway as a board observer. Conway serves as Global Head of Business Development at Elanco Animal Health (NYSE: ELAN).

The appointment follows an exclusive global license agreement between the companies for Monepantel, the active pharmaceutical ingredient in Neurizon's NUZ-001 drug candidate, announced in July 2025. The agreement provides Neurizon access to animal safety data and manufacturing data needed for clinical trials and potential regulatory approvals.

Conway brings over 20 years of experience in healthcare and animal health industries. She joined Elanco in 2020 after working in investment banking at Macquarie

Elanco executive joins Neurizon board as observer

Wed, 26 Nov 2025 18:16:41 -0400

Neurizon Therapeutics Limited (ASX: NUZ; OTCQB: NUZTF) announced the appointment of Justine Conway as a board observer. Conway serves as Global Head of Business Development at Elanco Animal Health (NYSE: ELAN).

The appointment follows an exclusive global license agreement between the companies for Monepantel, the active pharmaceutical ingredient in Neurizon's NUZ-001 drug candidate, announced in July 2025. The agreement provides Neurizon access to animal safety data and manufacturing data needed for clinical trials and potential regulatory approvals.

Conway brings over 20 years of experience in healthcare and animal health industries. She joined Elanco in 2020 after working in investment banking at Macquarie

Elanco executive joins Neurizon board as observer

Wed, 26 Nov 2025 18:16:41 -0400

Neurizon Therapeutics Limited (ASX: NUZ; OTCQB: NUZTF) announced the appointment of Justine Conway as a board observer. Conway serves as Global Head of Business Development at Elanco Animal Health (NYSE: ELAN).

The appointment follows an exclusive global license agreement between the companies for Monepantel, the active pharmaceutical ingredient in Neurizon's NUZ-001 drug candidate, announced in July 2025. The agreement provides Neurizon access to animal safety data and manufacturing data needed for clinical trials and potential regulatory approvals.

Conway brings over 20 years of experience in healthcare and animal health industries. She joined Elanco in 2020 after working in investment banking at Macquarie

Elanco executive joins Neurizon board as observer

Wed, 26 Nov 2025 18:16:41 -0400

Neurizon Therapeutics Limited (ASX: NUZ; OTCQB: NUZTF) announced the appointment of Justine Conway as a board observer. Conway serves as Global Head of Business Development at Elanco Animal Health (NYSE: ELAN).

The appointment follows an exclusive global license agreement between the companies for Monepantel, the active pharmaceutical ingredient in Neurizon's NUZ-001 drug candidate, announced in July 2025. The agreement provides Neurizon access to animal safety data and manufacturing data needed for clinical trials and potential regulatory approvals.

Conway brings over 20 years of experience in healthcare and animal health industries. She joined Elanco in 2020 after working in investment banking at Macquarie

Elanco executive joins Neurizon board as observer

Wed, 26 Nov 2025 18:16:41 -0400

Neurizon Therapeutics Limited (ASX: NUZ; OTCQB: NUZTF) announced the appointment of Justine Conway as a board observer. Conway serves as Global Head of Business Development at Elanco Animal Health (NYSE: ELAN).

The appointment follows an exclusive global license agreement between the companies for Monepantel, the active pharmaceutical ingredient in Neurizon's NUZ-001 drug candidate, announced in July 2025. The agreement provides Neurizon access to animal safety data and manufacturing data needed for clinical trials and potential regulatory approvals.

Conway brings over 20 years of experience in healthcare and animal health industries. She joined Elanco in 2020 after working in investment banking at Macquarie

Elanco executive joins Neurizon board as observer

Wed, 26 Nov 2025 18:16:41 -0400

Neurizon Therapeutics Limited (ASX: NUZ; OTCQB: NUZTF) announced the appointment of Justine Conway as a board observer. Conway serves as Global Head of Business Development at Elanco Animal Health (NYSE: ELAN).

The appointment follows an exclusive global license agreement between the companies for Monepantel, the active pharmaceutical ingredient in Neurizon's NUZ-001 drug candidate, announced in July 2025. The agreement provides Neurizon access to animal safety data and manufacturing data needed for clinical trials and potential regulatory approvals.

Conway brings over 20 years of experience in healthcare and animal health industries. She joined Elanco in 2020 after working in investment banking at Macquarie

Elanco executive joins Neurizon board as observer

Wed, 26 Nov 2025 18:16:41 -0400

Neurizon Therapeutics Limited (ASX: NUZ; OTCQB: NUZTF) announced the appointment of Justine Conway as a board observer. Conway serves as Global Head of Business Development at Elanco Animal Health (NYSE: ELAN).

The appointment follows an exclusive global license agreement between the companies for Monepantel, the active pharmaceutical ingredient in Neurizon's NUZ-001 drug candidate, announced in July 2025. The agreement provides Neurizon access to animal safety data and manufacturing data needed for clinical trials and potential regulatory approvals.

Conway brings over 20 years of experience in healthcare and animal health industries. She joined Elanco in 2020 after working in investment banking at Macquarie

Elanco executive joins Neurizon board as observer

Wed, 26 Nov 2025 18:16:41 -0400

Neurizon Therapeutics Limited (ASX: NUZ; OTCQB: NUZTF) announced the appointment of Justine Conway as a board observer. Conway serves as Global Head of Business Development at Elanco Animal Health (NYSE: ELAN).

The appointment follows an exclusive global license agreement between the companies for Monepantel, the active pharmaceutical ingredient in Neurizon's NUZ-001 drug candidate, announced in July 2025. The agreement provides Neurizon access to animal safety data and manufacturing data needed for clinical trials and potential regulatory approvals.

Conway brings over 20 years of experience in healthcare and animal health industries. She joined Elanco in 2020 after working in investment banking at Macquarie

Elanco executive joins Neurizon board as observer

Wed, 26 Nov 2025 18:16:41 -0400

Neurizon Therapeutics Limited (ASX: NUZ; OTCQB: NUZTF) announced the appointment of Justine Conway as a board observer. Conway serves as Global Head of Business Development at Elanco Animal Health (NYSE: ELAN).

The appointment follows an exclusive global license agreement between the companies for Monepantel, the active pharmaceutical ingredient in Neurizon's NUZ-001 drug candidate, announced in July 2025. The agreement provides Neurizon access to animal safety data and manufacturing data needed for clinical trials and potential regulatory approvals.

Conway brings over 20 years of experience in healthcare and animal health industries. She joined Elanco in 2020 after working in investment banking at Macquarie